EDWARDS LIFESCIENCES CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) 7.
ACQUISITIONS (Continued) was recorded to goodwill.
The following table summarizes the fair values of the assets acquired and liabilities assumed (in millions):
## Table 0 ##
Goodwill includes expected synergies and other benefits the Company believes will result from the acquisition.
Goodwill was assigned to the Company’s United States segment and is not deductible for tax purposes.
IPR&D has been capitalized at fair value as an intangible asset with an indefinite life and will be assessed for impairment in subsequent periods.
The fair value of the IPR&D was determined using the income approach.
This approach determines fair value based on cash flow projections which are discounted to present value using a risk-adjusted rate of return.
The discount rate used to determine the fair value of the IPR&D was 16.5%.
Completion of successful design developments, bench testing, pre-clinical studies and human clinical studies are required prior to selling any product.
The risks and uncertainties associated with completing development within a reasonable period of time include those related to the design, development, and manufacturability of the product, the success of pre-clinical and clinical studies, and the timing of regulatory approvals.
The valuation assumed $97.7 million of additional research and development expenditures would be incurred prior to the date of product introduction, and the Company does not currently anticipate significant changes to forecasted research and development expenditures associated with the CardiAQ program.
The Company’s valuation model also assumed net cash inflows would commence in late 2018, if successful clinical trial experiences lead to a CE mark approval.
Upon completion of development, the underlying research and development intangible asset will be amortized over its estimated useful life.
The Company disclosed in early February 2017 that it had voluntarily paused enrollment in its clinical trials for the Edwards-CardiAQ valve to perform further design validation testing on a feature of the valve.
This testing has been completed and, in collaboration with clinical investigators, the Company has decided to resume screening patients for enrollment in its clinical trials.
The results of operations for CardiAQ have been included in the accompanying consolidated financial statements from the date of acquisition.
Pro forma results have not been presented as the results of CardiAQ are not material in relation to the consolidated financial statements of the Company.8.
GOODWILL AND OTHER INTANGIBLE ASSETS On July 3, 2015, the Company acquired CardiAQ (see Note 7).
This transaction resulted in an increase to goodwill of $258.9 million and IPR&D of $190.0 million.
## Table 1 ##
(1) Of these amounts, $1,985, $2,039, $2,276, $2,457, $798, $853, $889, and $852, respectively, were from related parties.
(2) Of these amounts, $783, $933, $1,049, $1,052, $373, $321, $278 and $262, respectively, were from related parties.
(3) Of these amounts, $302, $378, $363, $486, $187, $207, $201 and $320, respectively, were from related parties.
(4) Of these amounts, $9, $10, $9, $7, $7, $5, $6 and $0, respectively, were from related parties.
(5) Of these amounts, $61, $64, $60, $58, $31, $22, $32 and $48, respectively, were from related parties.
(6) Of these amounts, $90, $58, $36, $30, $23, $33, $33 and $24, respectively, were from related parties.
(7) Of these amounts, $42, $38, $37, $35, $16, $15, $16 and $16, respectively, were from related parties.
Table of Contents Effects of Inflation Because the majority of our assets are liquid in nature, they are not significantly affected by inflation.
However, the rate of inflation may affect our expenses, such as employee compensation, office leasing costs and communications expenses, which may not be readily recoverable in the prices of our services.
To the extent inflation results in rising interest rates and has other adverse effects on the securities markets, it may adversely affect our financial position and results of operations.
Contractual Obligations and Commitments As of December 31, 2010, we had the following contractual obligations and commitments:
## Table 2 ##
We enter into foreign currency forward contracts with a noncontrolling stockholder broker-dealer client to hedge the exposure to variability in foreign currency cash flows resulting from the net investment in our U. K.  subsidiary.
As of December 31, 2010, the notional value of the foreign currency forward contract outstanding was $29.1 million and the gross and net fair value liability was $0.3 million.
As of December 31, 2010, we had unrecognized tax benefits of $3.3 million.
Due to the nature of the underlying positions, it is not currently possible to schedule the future payment obligations by period.
In January 2011, our board of directors approved a quarterly dividend to be paid to the holders of the outstanding shares of capital stock.
A cash dividend of $0.09 per share of voting and non-voting common stock outstanding will be payable on March 2, 2011 to stockholders of record as of the close of business on February 16, 2011.
We expect the total amount payable to be approximately $3.4 million.
Recent Accounting Pronouncements See Note 2 to the Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for a discussion of recent accounting pronouncements.
Market risk is the risk of the loss resulting from adverse changes in market rates and prices, such as interest rates and foreign currency exchange rates.
Market Risk The global financial services business is, by its nature, risky and volatile and is directly affected by many national and international factors that are beyond our control.
Any one of these factors may cause a substantial decline in the U. S.  and global financial services markets, resulting in reduced trading volume and revenues.
These events could have a material adverse effect on our business, financial condition and results of operations.
As of December 31, 2010, we had a $72.6 million investment in securities available-for-sale.
Adverse movements, such as a 10% decrease in the value of these securities or a downturn or disruption in the markets for these securities, could result in a substantial loss.
In addition, principal gains and losses resulting from these securities could on occasion have a disproportionate effect, positive or negative, on our financial condition and results of operations for any particular reporting period.
See also Item 1A .
Risk Factors , “Risks Related to Our Industry — Economic, political and market factors beyond our control could reduce demand for our services and harm our business, and our profitability could suffer .
”

<table><tr><td>Current assets</td><td>$28.1</td></tr><tr><td>Property and equipment, net</td><td>0.2</td></tr><tr><td>Goodwill</td><td>258.9</td></tr><tr><td>IPR&D</td><td>190.0</td></tr><tr><td>Current liabilities assumed</td><td>-32.9</td></tr><tr><td>Deferred income taxes</td><td>-66.0</td></tr><tr><td>Contingent consideration</td><td>-30.3</td></tr><tr><td>Total cash purchase price</td><td>348.0</td></tr><tr><td>Less: cash acquired</td><td>-27.9</td></tr><tr><td>Total cash purchase price, net of cash acquired</td><td>$320.1</td></tr></table>
<table><tr><td></td><td colspan="8"> Three Months Ended</td></tr><tr><td></td><td> Mar 31,  2009</td><td> Jun 30,  2009</td><td> Sep 30,  2009</td><td> Dec 31,  2009</td><td> Mar 31,  2010</td><td> Jun 30,  2010</td><td> Sep 30,  2010</td><td> Dec 31,  2010</td></tr><tr><td></td><td colspan="8"> (In thousands)</td></tr><tr><td> Revenues</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Commissions</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>U.S. high-grade -1</td><td>$13,515</td><td>$13,808</td><td>$16,306</td><td>$18,928</td><td>$19,776</td><td>$20,249</td><td>$21,537</td><td>$22,234</td></tr><tr><td>Eurobond -2</td><td>4,142</td><td>4,712</td><td>5,497</td><td>5,988</td><td>5,492</td><td>4,669</td><td>4,075</td><td>4,420</td></tr><tr><td>Other -3</td><td>2,789</td><td>3,310</td><td>3,486</td><td>3,651</td><td>4,039</td><td>4,542</td><td>5,540</td><td>5,607</td></tr><tr><td>Total commissions</td><td>20,446</td><td>21,830</td><td>25,289</td><td>28,567</td><td>29,307</td><td>29,460</td><td>31,152</td><td>32,261</td></tr><tr><td>Technology products andservices -4</td><td>2,023</td><td>2,096</td><td>2,601</td><td>3,058</td><td>3,164</td><td>3,251</td><td>3,455</td><td>3,778</td></tr><tr><td>Information and user accessfees -5</td><td>1,655</td><td>1,504</td><td>1,519</td><td>1,574</td><td>1,634</td><td>1,722</td><td>1,603</td><td>1,722</td></tr><tr><td>Interest income -6</td><td>332</td><td>234</td><td>314</td><td>342</td><td>291</td><td>315</td><td>301</td><td>285</td></tr><tr><td>Other -7</td><td>176</td><td>175</td><td>286</td><td>418</td><td>488</td><td>578</td><td>902</td><td>559</td></tr><tr><td>Total revenues</td><td>24,632</td><td>25,839</td><td>30,009</td><td>33,959</td><td>34,884</td><td>35,326</td><td>37,413</td><td>38,605</td></tr><tr><td> Expenses</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Employee compensation andbenefits</td><td>11,442</td><td>11,917</td><td>13,127</td><td>13,788</td><td>13,933</td><td>14,189</td><td>14,326</td><td>13,998</td></tr><tr><td>Depreciation and amortization</td><td>1,791</td><td>1,679</td><td>1,654</td><td>1,666</td><td>1,616</td><td>1,622</td><td>1,560</td><td>1,552</td></tr><tr><td>Technology and communications</td><td>2,242</td><td>2,120</td><td>2,029</td><td>2,045</td><td>2,417</td><td>2,353</td><td>2,543</td><td>2,669</td></tr><tr><td>Professional and consulting fees</td><td>1,879</td><td>1,613</td><td>1,645</td><td>1,732</td><td>2,138</td><td>1,990</td><td>2,241</td><td>2,134</td></tr><tr><td>Occupancy</td><td>676</td><td>693</td><td>706</td><td>1,054</td><td>938</td><td>707</td><td>706</td><td>646</td></tr><tr><td>Marketing and advertising</td><td>645</td><td>708</td><td>651</td><td>878</td><td>628</td><td>759</td><td>679</td><td>1,009</td></tr><tr><td>General and administrative</td><td>1,226</td><td>1,373</td><td>1,654</td><td>1,757</td><td>2,129</td><td>1,850</td><td>1,834</td><td>2,152</td></tr><tr><td>Total expenses</td><td>19,901</td><td>20,103</td><td>21,466</td><td>22,920</td><td>23,799</td><td>23,470</td><td>23,889</td><td>24,160</td></tr><tr><td>Income before income taxes</td><td>4,731</td><td>5,736</td><td>8,543</td><td>11,039</td><td>11,085</td><td>11,856</td><td>13,524</td><td>14,445</td></tr><tr><td>Provision for income taxes</td><td>1,892</td><td>2,549</td><td>3,903</td><td>5,603</td><td>4,384</td><td>4,687</td><td>4,913</td><td>5,498</td></tr><tr><td>Net income</td><td>$2,839</td><td>$3,187</td><td>$4,640</td><td>$5,436</td><td>$6,701</td><td>$7,169</td><td>$8,611</td><td>$8,947</td></tr></table>
<table><tr><td></td><td colspan="5"> Payments due by period</td></tr><tr><td></td><td> Total</td><td> Less than  1 year</td><td> 1 - 3 years</td><td> 3 - 5 years</td><td> More than  5 years</td></tr><tr><td></td><td colspan="5"> (In thousands)</td></tr><tr><td>Operating leases</td><td>$21,394</td><td>$1,843</td><td>$3,595</td><td>$3,770</td><td>$12,186</td></tr><tr><td>Capital leases</td><td>1,036</td><td>336</td><td>658</td><td>42</td><td>—</td></tr><tr><td>Foreign currencyforward contract</td><td>29,454</td><td>29,454</td><td>—</td><td>—</td><td>—</td></tr><tr><td></td><td>$51,884</td><td>$31,633</td><td>$4,253</td><td>$3,812</td><td>$12,186</td></tr></table>

Question: In the section with largest amount of Eurobond -2, what's the sum of Other -3 and Total commissions ? (in thousand)
Answer: 32218